Vitality Biopharma Sponsors Clinical Research Forum on Ending Opioid Epidemic
- Lack of effective response drives Los Angeles meeting to discuss immediate reduction of opiate painkillers
LOS ANGELES, June 05, 2018 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (OTCQB:VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids as an alternative to opiate abuse, today announced its sponsorship and organization of a key clinical research symposium on June 11th in Los Angeles.
‘Engineering an End to the Opioid Epidemic’ is both the name of the event as well as the title of the introductory presentation by Robert Brooke, CEO of Vitality Biopharma. The event is being held in the Glass Lounge of the InterContinental Hotel Century City, 2151 Avenue of the Stars, Los Angeles.
Date: Monday, June 11, 2018
Location: Glass Lounge, InterContinental Hotel Los Angeles Century City (Map)
Times: 4:00pm to 7:00pm Pacific
Presenters:
- Robert Brooke, CEO, Vitality Biopharma, Bioengineer
- Dr. Reef Karim, Psychiatrist, Addiction medicine physician, CNN Correspondent, UCLA Asst. Professor
- Dr. Sherry Yafai, Emergency medicine physician, ReLeaf Institute
- Dr. Caroline MacCallum, Complex pain specialist, Clinical Instructor, Univ of British Columbia School of Medicine
Physicians, researchers, patients, and patient advocates are all welcome to attend. Please RSVP soon as seating is limited for this event. To register click here.
About Engineering an End to the Opioid Epidemic Symposium
Despite increasing recognition of the opioid epidemic and the magnitude of the problem, there has not been a coordinated and effective response to it. There are more than 2 million Americans that are still opiate-dependent, and there are no well-established and reliable methods that have been established to help these individuals safely reduce and eliminate their use. In a clinical research symposium sponsored by Vitality Biopharma, physicians and researchers are meeting in Los Angeles to discuss what can be done today in the U.S., and rapidly, in order to reduce and eliminate use of opiate painkillers especially through use of cannabinoids. For more information, click here, email info@vitality.bio, or call 1-530-231-7800.
About Vitality Biopharma (OTCQB:VBIO)
Vitality Biopharma is dedicated to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. For more information, visit: www.vitality.bio. Follow us on Facebook, Twitter and LinkedIn.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the United States Securities Act of 1933, as amended and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
Contact
Vitality Biopharma
Investor Relations
info@vitality.bio
1-530-231-7800
www.vitality.bio
EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.
